Cardiac Phenotype-Genotype Associations in DMD/BMD: A Meta-Analysis and Systematic Review

Overview

Journal Pediatr Cardiol

Specialties Cardiology & Vascular Diseases
Pediatrics

Date 2020 Oct 10

PMID 33037470

Citations 3

Authors

Huan Zhou

Manli Fu

Bing Mao

Li Yuan

Affiliations

Soon will be listed here.

Abstract

Cardiac involvement of Duchenne and Becker muscular dystrophies (DMD/BMD) is the most common cause of fatal outcomes. It is still unclear whether some DMD/BMD gene mutations might be predictive of cardiac involvement. In this study, we provide a comprehensive overview on genotypes of cardiac disease in DMD/BMD. We systematically searched the PubMed/Medline, EMBASE and Cochrane electronic databases. Search results were filtered to include only human studies, English language and all dates up to August 2019. We summarized and extensively reviewed all studies that passed the selection criteria and performed a meta-analysis on key genotype parameters of cardiac disease in DMD/BMD. Of 3450 articles scanned, we included 18 studies from 9 regions in the meta-analysis. The pooled studies included 2661 DMD/BMD patients and 1324 DMD/BMD patients with cardiac disease. The most common mutation type was exon deletion, with a pooled frequency of 90% (P < 0.01). In DMD/BMD patients with cardiac dysfunction, a higher frequency of involvement of exons 45 and 46 was found in DMD/BMD patients with cardiac dysfunction. This might be predictive of cardiac involvement in patients with DMD/BMD.

Citing Articles

Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update.

Lupu M, Pintilie I, Teleanu R, Marin G, Vladacenco O, Severin E Int J Mol Sci. 2025; 26(4).

PMID: 40004149 PMC: 11855830. DOI: 10.3390/ijms26041685.

DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy.

Ge L, Yang Y, Yang Y, Chen Y, Tao N, Zhang L Open Med (Wars). 2024; 19(1):20240916.

PMID: 39588385 PMC: 11587917. DOI: 10.1515/med-2024-0916.

Non-invasive ventilation in neuromuscular diseases: should we use higher levels of ventilatory support?.

Leotard A, Delorme M, Hartley S, Khouri C, Lebret M, Lofaso F Sleep Breath. 2022; 27(2):673-677.

PMID: 35725863 DOI: 10.1007/s11325-022-02658-3.

Integrated Pharmacogenetics Analysis of the Three Fangjis Decoctions for Treating Arrhythmias Based on Molecular Network Patterns.

Wei P, Long D, Tan Y, Xing W, Li X, Yang K Front Cardiovasc Med. 2022; 8:726694.

PMID: 35004871 PMC: 8739471. DOI: 10.3389/fcvm.2021.726694.

References

Muntoni F, Torelli S, Ferlini A . Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003; 2(12):731-40. DOI: 10.1016/s1474-4422(03)00585-4. View

EMERY A . Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991; 1(1):19-29. DOI: 10.1016/0960-8966(91)90039-u. View

Kohler M, Clarenbach C, Bahler C, Brack T, Russi E, Bloch K . Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2008; 80(3):320-5. DOI: 10.1136/jnnp.2007.141721. View

McNally E, Kaltman J, Benson D, Canter C, Cripe L, Duan D . Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation. 2015; 131(18):1590-8. PMC: 4573596. DOI: 10.1161/CIRCULATIONAHA.114.015151. View

Birnkrant D, Ararat E, Mhanna M . Cardiac phenotype determines survival in Duchenne muscular dystrophy. Pediatr Pulmonol. 2015; 51(1):70-6. DOI: 10.1002/ppul.23215. View

Kamdar F, Garry D . Dystrophin-Deficient Cardiomyopathy. J Am Coll Cardiol. 2016; 67(21):2533-46. DOI: 10.1016/j.jacc.2016.02.081. View

Cox G, Kunkel L . Dystrophies and heart disease. Curr Opin Cardiol. 1997; 12(3):329-43. View

Melacini P, Fanin M, Danieli G, Villanova C, Martinello F, Miorin M . Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation. 1996; 94(12):3168-75. DOI: 10.1161/01.cir.94.12.3168. View

Burch M, Siddiqi S, Celermajer D, Scott C, Bull C, Deanfield J . Dilated cardiomyopathy in children: determinants of outcome. Br Heart J. 1994; 72(3):246-50. PMC: 1025510. DOI: 10.1136/hrt.72.3.246. View

10.

Kaspar R, Allen H, Ray W, Alvarez C, Kissel J, Pestronk A . Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet. 2009; 2(6):544-51. PMC: 2826810. DOI: 10.1161/CIRCGENETICS.109.867242. View

11.

Nigro G, Comi L, Politano L, Bain R . The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990; 26(3):271-7. DOI: 10.1016/0167-5273(90)90082-g. View

12.

Raman S, Hor K, Mazur W, Halnon N, Kissel J, He X . Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015; 14(2):153-61. PMC: 4361281. DOI: 10.1016/S1474-4422(14)70318-7. View

13.

Viollet L, Thrush P, Flanigan K, Mendell J, Allen H . Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol. 2012; 110(1):98-102. DOI: 10.1016/j.amjcard.2012.02.064. View

14.

Kwon S, Lee B, Hong B, Kim J, Choi E, Sung J . Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. Int J Cardiol. 2012; 167(5):1990-4. DOI: 10.1016/j.ijcard.2012.05.007. View

15.

Rhodes J, Margossian R, Darras B, Colan S, Jenkins K, Geva T . Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol. 2007; 29(2):343-51. DOI: 10.1007/s00246-007-9113-z. View

16.

Markham L, Kinnett K, Wong B, Benson D, Cripe L . Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008; 18(5):365-70. DOI: 10.1016/j.nmd.2008.03.002. View

17.

Markham L, Spicer R, Khoury P, Wong B, Mathews K, Cripe L . Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005; 26(6):768-71. DOI: 10.1007/s00246-005-0909-4. View

18.

Houde S, Filiatrault M, Fournier A, Dube J, Darcy S, Berube D . Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol. 2008; 38(3):200-6. DOI: 10.1016/j.pediatrneurol.2007.11.001. View

19.

Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M . All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol. 2013; 61(9):948-54. DOI: 10.1016/j.jacc.2012.12.008. View

20.

Jefferies J, Eidem B, Belmont J, Craigen W, Ware S, Fernbach S . Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005; 112(18):2799-804. DOI: 10.1161/CIRCULATIONAHA.104.528281. View